Emergent BioSolutions | EBS - Interest Expense On Debt


Emergent BioSolutions reported $17.9M in Interest Expense on Debt for its fiscal quarter ending in March of 2023.





Interest Expense On Debt Change Date
Acadia Pharmaceuticals USD 0 4.12M Sep/2024
Akebia Therapeutics 362.52M 357.69M Mar/2026
ALKERMES USD 20.89M 8.62M Mar/2026
Alnylam Pharmaceuticals USD 69.29M 60.05M Mar/2026
Amarin USD 3K 5K Dec/2024
ANI Pharmaceuticals USD 4.41M 316K Dec/2025
BioMarin Pharmaceutical USD 14.96M 12.18M Mar/2026
Coherus Biosciences USD 2.25M 76K Dec/2025
Exelixis USD 23.4M 3.9M Sep/2023
Glaxosmithkline GBP 177.95M 6.05M Sep/2025
Heron Therapeutics USD 600K 100K Dec/2024
Ionis Pharmaceuticals USD 17M 1000K Mar/2026
Ironwood Pharmaceuticals USD 8.74M 506K Dec/2024
Lexicon Pharmaceuticals USD 2.03M 124K Dec/2025
Lonza CHF 84M 14M Jun/2025
Merck USD 479M 67M Mar/2026
Moderna USD 11.49B 36B Mar/2026
Myriad Genetics USD 4.4M 600K Dec/2025
Nektar Therapeutics USD 9.77M 3.75M Dec/2025
Neurocrine Biosciences USD 1.1M 0 Mar/2024
Pacira USD 3.7M 193K Mar/2026
Pfizer USD 671M 40M Mar/2026
PTC Therapeutics USD 2.87B 2.82B Mar/2026
Sanofi EUR 178M 203M Mar/2026
Sarepta Therapeutics USD 20.84M 13.28M Dec/2025
United Therapeutics USD 3.1M 100K Dec/2025
Vanda Pharmaceuticals -1.37B 1.97B Dec/2025
Xoma USD 3.4M 150K Jun/2024